🇺🇸 FDA
Pipeline program

CRD-TMH-001

CS-CRD-TMH-001

Phase 1 small_molecule active

Quick answer

CRD-TMH-001 for Duchenne Muscular Dystrophy is a Phase 1 program (small_molecule) at Ultragenyx Pharmaceutical with 1 ClinicalTrials.gov record(s).

Program details

Company
Ultragenyx Pharmaceutical
Indication
Duchenne Muscular Dystrophy
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials